Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.


David S. Pisetsky, MD, PhD |
Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

Patrice Fusillo |
During ACR Convergence 2021 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the winners of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

Kade L. Paterson, PhD, BPod, BAppSci(Hons), Marian T. Hannan, DSc, MPH, Lara Chapman, MSc, BPod, Edward Roddy, DM, FRCP, Hylton B. Menz, PhD, BPod, & Catherine Bowen, PhD, BPod |
The high prevalence and significant burden of osteoarthritis (OA) are well known. But it’s becoming apparent that OA research efforts don’t necessarily match disease prevalence or disability. The International Foot and Ankle Osteoarthritis Consortium (IFOAC) is an international organization of volunteers that seeks to highlight a major and often overlooked problem in OA research—foot and…

Some were furious. State by state, laws were enacted to ensure compliance. In most states, the laws were accompanied by a modest fine, as an added incentive. By the time the laws were written, most understood they were based on good science and common sense. The potential to save lives and prevent tragedy was finally…

Vaidehi R. Chowdhary, MD, & Jane E. Dee, BA, MALS |
The COVID-19 pandemic exacerbated wide disparities that exist in the U.S. healthcare system. During the pandemic, the clinical practice in the Section of Rheumatology, Allergy & Immunology at Yale School of Medicine (YSM), New Haven, Conn., rapidly pivoted from face-to-face visits to telehealth to keep our patients and providers safe. Many patients quickly adapted and…

Mary Choy, PharmD, BCGP, FASHP |
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…

Contraception, disease control, family planning and managing life with an infant—five experts addressed these concerns and more for patients with rheumatic disease during a special online webinar.

Kelli Allen, PhD, believes strongly in the mission of AC&R, and as the journal’s new editor in chief, it’s now in her hands to carry that mission forward. Dr. Allen assumed the role on July 1, following the decade-long tenure of Dr. Hannan. “Everyone has been very generous with their time and the managing editors…

On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…